Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
Authors:
- M. VillarMVM. Villar
- G. SotgiuG. Sotgiu
- L. D'AMbrosioLDL. D'AMbrosio
- E. RaymundoERE. Raymundo
- L. FernandesLFL. Fernandes
- J. BarbedoJBJ. Barbedo
- N. DiogoNDN. Diogo
- C. LangeCLC. Lange
- R. CentisRCR. Centis
- G.B. MiglioriGMG.B. Migliori
- 31 August 2011
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 38 (3) , 730-733
Abstract
To the Editors: Treatment of multidrug-resistant (MDR) tuberculosis (TB) (defined as in vitro resistance to at least isoniazid and rifampicin, the two most potent first-line drugs for TB treatment) and extensively drug-resistant (XDR)-TB (defined as in vitro resistance to isoniazid and rifampicin plus any fluoroquinolone and at least one of the injectable drugs: amikacin, capreomycin or kanamycin) is still a major problem from both a clinical and a public health perspective [1–5]. Treatment outcomes for complicated MDR-TB cases (those with additional resistance beyond isoniazid and rifampicin) and XDR-TB cases being still poor, the need for information on the safety, tolerability and efficacy of other antibiotics that are potentially useful in their treatment is urgent [6–9]. In vitro and pharmacological data suggest that linezolid, an oxazolidinone antibiotic, could be useful in treating mycobacterial infections, including MDR-TB [9–11]. However, clinical experience with the off-label use of linezolid is still limited to case reports and small case series involving nontuberculous mycobacterial diseases [12] and TB, the four largest cohorts including 10 [13], 12 [14], 30 [15] and 85 cases (but only 45 with information on efficacy) [9], respectively. The aim of this study was to evaluate the safety, tolerability and efficacy of linezolid in a cohort of patients with MDR/XDR-TB from Portugal. Clinical information necessary to study safety, tolerability and efficacy was prospectively collected on all MDR-TB cases treated with linezolid in Portugal between 2004 and 2009, with the exception of one case who started the treatment in 2003 (whose information was …Keywords
This publication has 9 references indexed in Scilit:
- Linezolid in the Treatment of Multidrug‐Resistant TuberculosisClinical Infectious Diseases, 2010
- A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosisEuropean Respiratory Journal, 2009
- Epidemiology and clinical management of XDR-TB: a systematic review by TBNETEuropean Respiratory Journal, 2009
- Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis*Chest, 2008
- Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis casesEuropean Respiratory Journal, 2008
- Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?: Table 1—European Respiratory Journal, 2008
- Clinical and operational value of the extensively drug-resistant tuberculosis definitionEuropean Respiratory Journal, 2007
- Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten casesJournal of Infection, 2006
- Oxazolidinone antibioticsThe Lancet, 2001